Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest T Hawk

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|August 15, 2022
Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018Abbey B Berenson, Mihyun Chang, Ernest T Hawk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 21, 2010
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trialMonica M Bertagnolli, Meier Hsu, Ernest T Hawk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 28, 2011
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenomaAndrew T Chan, Meier Hsu, Ann G Zauber, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 19, 2003
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff, Joyce A O'Shaughnessy, Gary B Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for biospecimen-based assessment modalitiesSudhir Srivastava, Joe W Gray, Brian J Reid, et al.
Cancer|February 8, 2022
Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questionsJohn B Kisiel, Nickolas Papadopoulos, Minetta C Liu, et al.
Cancer Research|October 3, 2003
Frontiers in cancer prevention researchAnita L Sabichi, Marie-France Demierre, Ernest T Hawk, et al.
CA: a Cancer Journal for Clinicians|August 19, 2015
Molecular cancer prevention: Current status and future directionsKaren Colbert Maresso, Kenneth Y Tsai, Powel H Brown, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 26, 2014
Convergence of nanotechnology and cancer prevention: are we there yet?David G Menter, Sherri L Patterson, Craig D Logsdon, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 6, 2011
C-reactive protein and risk of colorectal adenoma according to celecoxib treatmentAndrew T Chan, Camelia S Sima, Ann G Zauber, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Cancer Prevention Research (Philadelphia, Pa.)|August 15, 2022
Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018Abbey B Berenson, Mihyun Chang, Ernest T Hawk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 21, 2010
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trialMonica M Bertagnolli, Meier Hsu, Ernest T Hawk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 28, 2011
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenomaAndrew T Chan, Meier Hsu, Ann G Zauber, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 19, 2003
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff, Joyce A O'Shaughnessy, Gary B Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for biospecimen-based assessment modalitiesSudhir Srivastava, Joe W Gray, Brian J Reid, et al.
Cancer|February 8, 2022
Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questionsJohn B Kisiel, Nickolas Papadopoulos, Minetta C Liu, et al.
Cancer Research|October 3, 2003
Frontiers in cancer prevention researchAnita L Sabichi, Marie-France Demierre, Ernest T Hawk, et al.
CA: a Cancer Journal for Clinicians|August 19, 2015
Molecular cancer prevention: Current status and future directionsKaren Colbert Maresso, Kenneth Y Tsai, Powel H Brown, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 26, 2014
Convergence of nanotechnology and cancer prevention: are we there yet?David G Menter, Sherri L Patterson, Craig D Logsdon, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 6, 2011
C-reactive protein and risk of colorectal adenoma according to celecoxib treatmentAndrew T Chan, Camelia S Sima, Ann G Zauber, et al.
Pageof 10